Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras sodium decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].
Molecular Weight:
228.26
Purity:
99.78
CAS Number:
[1254472-97-3]
Formula:
C13H17NaO2
Target:
Free Fatty Acid Receptor,GPR84
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted